PMID- 28419991
OWN - NLM
STAT- MEDLINE
DCOM- 20180208
LR  - 20191210
IS  - 1423-0216 (Electronic)
IS  - 1021-7401 (Linking)
VI  - 23
IP  - 5-6
DP  - 2016
TI  - Effect of Melatonin and Resveratrol against Memory Impairment and Hippocampal 
      Damage in a Rat Model of Vascular Dementia.
PG  - 318-331
LID - 10.1159/000454681 [doi]
AB  - OBJECTIVES: This study was intended to investigate whether treatment with 
      resveratrol and melatonin alone or in combination can exert neurorestorative 
      effects in a rat model of vascular dementia. METHODS: Briefly, male Wistar rats 
      were subjected to permanent bilateral common carotid artery occlusion (BCCAO) by 
      surgery. After 4 weeks, the cognitive deficits were assessed using the Morris 
      water maze and novel object recognition tests. The biochemical parameters of 
      oxidative stress and inflammation were also assessed. RESULTS: Rats in the BCCAO 
      group showed cognitive deficits, accompanied by oxidonitrosative stress, 
      neuroinflammation, and a reduction in brain-derived neurotrophic factor (BDNF) in 
      the hippocampus region. Moreover, the acetylcholinesterase activity in the 
      hippocampus was found to be increased in the BCCAO group compared to the sham 
      group. The 4-week treatment with melatonin (10 mg/kg) and resveratrol (20 mg/kg) 
      alone and in combination (melatonin 5 mg/kg and reseveratrol 10 mg/kg) caused a 
      significant improvement in the cognitive deficits induced by BCCAO, accompanied 
      by a reversal of oxidonitrosative stress, neuroinflammation, and BDNF depletion 
      in the hippocampus region. Additionally, the treatment with melatonin and 
      resveratrol significantly decreased acetylcholinesterase activity compared to in 
      the BCCAO group. Melatonin and resveratrol ameliorated the BDNF expression of 
      hippocampal protein. CONCLUSION: These results emphasize that coadministration of 
      melatonin and resveratrol can be beneficial in BCCAO-induced vascular dementia 
      through changes in BDNF expressions.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Shen, Dongfang
AU  - Shen D
AD  - Department of Neurology, The Fourth Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Tian, Xiaoyan
AU  - Tian X
FAU - Sang, Wenxu
AU  - Sang W
FAU - Song, Rongrong
AU  - Song R
LA  - eng
PT  - Journal Article
DEP - 20170419
PL  - Switzerland
TA  - Neuroimmunomodulation
JT  - Neuroimmunomodulation
JID - 9422763
RN  - 0 (Antioxidants)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Stilbenes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - GAN16C9B8O (Glutathione)
RN  - JL5DK93RCL (Melatonin)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Antioxidants/therapeutic use
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Dementia, Vascular/*complications/*pathology
MH  - Disease Models, Animal
MH  - Drug Therapy, Combination
MH  - Glutathione/metabolism
MH  - Hippocampus/*pathology
MH  - Interleukin-1beta/metabolism
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Maze Learning/drug effects
MH  - Melatonin/*therapeutic use
MH  - Memory Disorders/*drug therapy/*etiology
MH  - Models, Molecular
MH  - Rats
MH  - Rats, Wistar
MH  - Recognition, Psychology/drug effects
MH  - Resveratrol
MH  - Stilbenes/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Bilateral common carotid artery occlusion
OT  - Hippocampus
OT  - Morris water maze
OT  - Neuroinflammation
OT  - Oxidonitrosative stress
EDAT- 2017/04/19 06:00
MHDA- 2018/02/09 06:00
CRDT- 2017/04/19 06:00
PHST- 2016/09/02 00:00 [received]
PHST- 2016/11/21 00:00 [accepted]
PHST- 2017/04/19 06:00 [pubmed]
PHST- 2018/02/09 06:00 [medline]
PHST- 2017/04/19 06:00 [entrez]
AID - 000454681 [pii]
AID - 10.1159/000454681 [doi]
PST - ppublish
SO  - Neuroimmunomodulation. 2016;23(5-6):318-331. doi: 10.1159/000454681. Epub 2017 
      Apr 19.